Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

Overview of attention for article published in The Lancet, January 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 10 public wall posts from 10 users.

GWPCARE4: Étude de phase III sur l'utilisation du cannabidiol comme traitement anti-épileptique chez des patients avec le…

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-con…

CBD is effective against seizures in Lennox-Gastaut syndrome

Lancet. 2018 Jan 25. pii: S0140-6736(18)30136-3. doi: 10.1016/S0140-6736(18)30136-3. [Epub ahead of print]

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity, including 6 additional Facebook posts.